Study of the Aortic and Large Arterial Vessel Infections (Repia)

French Registry Studying the Characteristics and Prognosis of Aortic and Large Arterial Vessel Infections

Aortic or large arterial vessel infections are rare but serious infections. Their management is based on French and American expert opinions. The quality of evidence supporting these guidelines is low because most publications on the subject correspond to case series and few interventional studies have been performed to validate their management. However, referral centres for vascular surgery are frequently solicited to give their opinion on patients suffering from mycotic aneurysms. In addition, the last few decades have seen the improvement of vascular surgery techniques allowing the management of more and more patients, often elderly and comorbid. There has therefore been an increase in the incidence of infectious complications associated with this care. It is therefore essential to participate in research on aortic and large arterial vessel infections. For this, a monocentric cohort study seems to be an essential first step to better understand the polymorphism and complexity of these patients.

Study Overview

• Status: Recruiting
• Conditions: Prosthetic Infection; Aortic Infections and Inflammations; Mycotic Aneurysm; Arterial Infections and Inflammations

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Lefevre Benjamin, M.D.; Phone Number: +33383157654; Email: b.lefevre@chru-nancy.fr

Study Locations

• France
  • Lorraine
    • Vandoeuvre Les Nancy, Lorraine, France, 54511
      • Recruiting
      • Université de Lorraine, CHRU Nancy and APEMAC
      • Contact: Lefevre Benjamin, M.D.; Phone Number: +33383157654; Email: b.lefevre@chru-nancy.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All adults patients with proved aortic or large arterial vessel infection and without exclusion criteria.

Description

Inclusion Criteria:

• Age ≥ 18 years

• Aortic or large arterial vessel infection. The diagnosis is made on a number of criteria in favour of the diagnosis (at least 2 of the following 3 criteria):

  • Compatible clinical presentation: local or general inflammatory signs suggestive of a deep infection (fever, chills, scar discharge, fistula, febrile abdominal pain and low back pain, ...) or per-operative finding of an infection in contact with native or prosthetic vascular tissue
  • And/or biological (inflammatory syndrome) and/or imaging evidence (infectious sign on native, bioprosthetic or prosthetic vascular tissue on CT and/or PET scan) in favour of the diagnosis
  • And/or microbiological evidence (positive serologies, blood cultures or deep samples in favour of infection)

Exclusion Criteria:

• Patient who objected to participation in this protocol and data collection
• Pregnant woman, parturient or breastfeeding mother
• Person deprived of liberty by a judicial or administrative decision,
• Person subject to psychiatric care by virtue of articles L.3212-1 and L.3213-1 of the French public health code
• Person subject to a legal protection measure
• Person unable to give consent

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
one-year mortality	Study of all-cause mortality in patients with aortic vascular infection and large arterial vessels during the first year of follow-up after diagnosis.	one year after the diagnosis

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of prognostic factors associated with arterial vascular infections	Identification of prognostic factors in patients with aortic and large arterial vessel infection: a multivariate Cox model to identify factors associated with mortality or better survival	at the time of diagnosis and up to one year afterwards

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France
• Investigators: Principal Investigator: Lefèvre Benjamin, M.D., Université de Lorraine & CHRU de Nancy

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2023
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: December 7, 2022
• First Submitted That Met QC Criteria: December 19, 2022
• First Posted (Actual): December 21, 2022

Study Record Updates

• Last Update Posted (Actual): August 8, 2025
• Last Update Submitted That Met QC Criteria: August 6, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Disease Attributes; Aneurysm; Inflammation; Infections; Communicable Diseases; Aneurysm, Infected
• Other Study ID Numbers: Research on existing data

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No